As with other drugs, Rinvoq (upadacitinib) can cause side effects, such as upper respiratory infections, fever, and nausea. If you are not able to tolerate Rinvoq’s side effects, talk with your ...

In 2024, AbbVie reported that Skyrizi and Rinvoq accounted for about $5bn in ... or refraining from, any action on the basis of the content on our site.

Upadacitinib 1mg/mL; oral soln. Increased risk of serious infections (eg, TB, bacterial, viral, invasive fungal, or other opportunistic pathogens). Avoid in active, serious, or localized ...

AbbVie's would-be blockbuster Rinvoq has notched up another positive trial in Crohn's disease, showing that it can achieve clinical remission over a full year when used as a maintenance therapy.

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 57% to $3.78 billion, and Rinvoq, which logged a 46% gain to $1.83 billion. Chief Executive Robert Michael ...

AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 billion ... revenue growth rate for aesthetics through 2029. Price Action: ABBV shares are trading higher by 7.87% to $189. ...